
Originally published on https://sayerji.substack.com
While Washington debates injectable peptides, a peer-reviewed aging study showed that a humble sprouting grass could do what a thymus graft does, and almost no one followed up.
This year, peptides went mainstream.
This year, peptides went mainstream.
On February 27, 2026, the Secretary of Health and Human Services announced that about 14 of the 19 peptides the FDA had restricted from compounding would be reclassified. The list included BPC-157, thymosin alpha-1, TB-500, GHK-Cu, and MOTS-c (AJMC). In July, an FDA advisory committee narrowly voted to recommend six of them, including BPC-157 and the “longevity peptide” epitalon, for the compounding list. Agency scientists had argued against them (Latham & Watkins; PressAdvantage). Meanwhile, a gray market thrives, and the press says people “are turning themselves into lab rats” (The Guardian).

![FireShot-Capture-970---Pinktober’s-New-Alibi_-How-the-Screening-Establishment-Graded-Its-O_---[sayerji.substack.com].jpg](https://fls-a0de34a7-7f40-4480-890f-5c01779c21d4.laravel.cloud/6295/FireShot-Capture-970---Pinktober%E2%80%99s-New-Alibi_-How-the-Screening-Establishment-Graded-Its-O_---%5Bsayerji.substack.com%5D.jpg)

(
(



(
(
